Skip to content
- We wrote about the hugely unusual decision by Biogen last week.
- There is a sleuthing Reuter’s piece that reveals what happened behind the scenes of how we went from a failed trial to a drug filing.
- The sell-side haven’t been convinced either. Many expect the FDA to demand another trial.
WordPress Cookie Notice by Real Cookie Banner
